Unknown PHASE4 INTERVENTIONAL 2-arm NCT04659525

Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia

Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia

Sponsor: IRCCS San Raffaele

Conditions CKD Stage 5 Chronic Kidney Disease Requiring Chronic Dialysis Hypercholesterolemia

Interventions Evolocumab Ezetimibe Placebo

Updated 4 times since 2021 Last updated: Dec 13, 2020 Started: Nov 1, 2020 Primary completion: Nov 30, 2021 Completion: Dec 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates CKD Stage 5 and Chronic Kidney Disease Requiring Chronic Dialysis and is currently ongoing. IRCCS San Raffaele leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2023 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Jan 2023 [monthly]

Recruiting PHASE4

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

IRCCS San Raffaele
Policlinico Casilino ASL RMB

Data source: Policlinico Casilino ASL RMB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy